Table 1

Baseline characteristics and transplantation outcomes

VariableTotal (n=20 971)Sarcoid (n=695, 3.3%)Non-sarcoid (n=20 201, 96.7%)p Value
Pretransplant
 Age, year, mean±SD50.2±15.049.9±8.750.2±15.10.55
 Males, n (%)11 165 (53.2)300 (43.0)10 865 (53.6)<0.001
 Caucasian, n (%)18 309 (87.3)227 (32.6)18 082 (89.2)<0.001
 Waiting time, month, median (range)5.3 (0–195)5.9 (0–97)5.3 (0–195)0.24
Life support, n (%)
 Inhaled NO18 (0.1)0 (0)18 (0.1)0.43
 Prostacyclin63 (0.3)4 (0.5)59 (0.3)0.41
 ECMO-bridge43 (0.2)0 (0)43 (0.2)0.22
 Mechanical ventilation312 (1.5)5 (0.7)307 (1.5)0.10
Transplant
 Graft ischemic time, hour, mean±SD4.8±1.75.1±1.84.8±1.7<0.001
 Double lung transplant, n (%)12 011 (57.3)480 (68.9)11 531 (56.9)<0.001
Donor
 Age, year, mean±SD31.9±14.233.7±13.731.8±14.1<0.001
 Male, n (%)12 861 (61.3)369 (52.9)12 492 (61.6)<0.001
 Caucasian, n (%)14 285 (68.1)432 (62)13 853 (68.3)<0.001
 LAS era, post, n (%)10 245 (49.0)381 (54.8)9864 (48.8)0.002
Post-transplant
 Survival
  Median (IQR), months63.4 (61.7–65.0)69.7 (60.2–79.3)63.1 (61.4–64.8)0.88
  1 year (%)727173
  5 years (%)475046
  10 years (%)262826
 Allograft dysfunction
  Retransplanted, n (%)787 (3.8)15 (2.2)772 (3.8)0.03
  BOS, n (%)7283 (35.6)222 (31.9)7061 (35.7)0.42
  New O2 requirement, n (%)1065 (27.8)129 (27.5)3936 (27.8)0.9
  • Prostacyclin in the intravenous or inhaled formulations.

  • BOS, post-transplant bronchioalveolitis obliterans syndrome; ECMO, extracorporeal membrane oxygenation; LAS, lung allocation score; NO, inhaled nitric oxide.